The global high-content screening market is currently witnessing strong growth. High content screening (HCS), or high content analysis, refers to an analytical method of automated microscopy that uses visualization tools to obtain quantitative data from cell populations. It is an integration of modern cell biology, flow cytometry and robotic handling that involves fluorescence imaging for analyzing various biochemical and physical characteristics of the sample cells. This aids in drug discovery, complex multivariate drug profiling and toxicity studies, while utilizing robots, detectors and software to monitor the entire process.
The increasing prevalence of neurodegenerative diseases across the globe, such as Alzheimer’s and Parkinson’s, is one of the key factors driving the market growth. The rising need for cost-effective drug discovery systems in the pharmaceutical industry is also providing a boost to the market growth. In comparison to the traditionally used methods, HCS solutions prove to be inexpensive and resource- and time-efficient for analyzing the potential toxicity of chemicals and complex substances. Advancements in informatics solutions and imaging instruments are acting as another growth-inducing factor. HCS equipment manufacturers are producing innovative equipment that is integrated with software platforms and artificial intelligence (AI) systems to enhance the visualization capabilities of the devices. In line with this, the development of automated systems for analyzing cell separation and scalability has further enhanced the adoption of HCS technology. Other factors, including the rising geriatric population and increasing investments in the research and development (R&D) of advanced screening systems, are projected to drive the market further. Looking forward, IMARC Group expects the market to register a CAGR of around 8% during 2020-2025.
Breakup by Product:
Cell Imaging and Analysis Systems
Reagents & Assay Kits
Breakup by Application:
Target Identification and Validation
Primary Screening and Secondary Screening
Breakup by End-User:
Pharmaceutical and Biotechnology Companies
Academic and Government Institutes
Contract Research Organizations (CROs)
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific, Yokogawa Electric Corporation, etc.
Key questions answered in this report:
How has the global high content screening market performed so far and how will it perform in the coming years?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global high content screening market and who are the key players?
What is the degree of competition in the industry?